ChromaDex (NASDAQ:CDXC) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of ChromaDex (NASDAQ:CDXC) in a research note issued to investors on Friday. The firm issued a buy rating on the stock.

A number of other analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of ChromaDex in a research report on Monday, March 17th. LADENBURG THALM/SH SH lifted their target price on ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a report on Wednesday, March 5th.

ChromaDex Stock Performance

ChromaDex has a fifty-two week low of $2.31 and a fifty-two week high of $9.18. The business has a 50-day moving average of $6.16 and a two-hundred day moving average of $5.44. The stock has a market capitalization of $611.50 million, a PE ratio of 787.29 and a beta of 2.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. D. E. Shaw & Co. Inc. raised its stake in shares of ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock valued at $5,365,000 after buying an additional 957,665 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in ChromaDex by 288.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock worth $3,517,000 after acquiring an additional 492,148 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in ChromaDex by 189.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company’s stock valued at $2,685,000 after acquiring an additional 331,014 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in ChromaDex during the fourth quarter valued at approximately $1,647,000. Finally, Renaissance Technologies LLC lifted its holdings in ChromaDex by 68.0% in the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after acquiring an additional 288,588 shares during the period. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.